However, after the occurrence of neutropenia-related deaths (7 patients [2%] receiving cabazitaxel in TROPIC overall), the Independent Data Monitoring Committee recommended that investigators strictly follow protocol-recommended dose modifications and treatment of neutropenia, as per American Society of Clinical Oncology (ASCO) guidelines, and that prophylactic G-CSF be used at the discretion of the investigator, except during Cycle 1 of the treatment. The gene discussed is CSF3; the disease is neutropenia.